By contrast, expression of EZH2 in cancer cells may dampen anti-tumor immunity and hinder the infiltration of the tumor by effector T cells through EZH2- and DNMT1-mediated epigenetic silencing of TH1-type chemokines (i.e., CXCL9 and CXCL10) [91, 92]. The gene discussed is CXCL10; the disease is neoplasm.